Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Receivables (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Receivables data on record, last reported at $182967.0 in Q4 2025.

  • For Q4 2025, Receivables fell 30.32% year-over-year to $182967.0; the TTM value through Dec 2025 reached $182967.0, down 30.32%, while the annual FY2025 figure was $465104.0, N/A changed from the prior year.
  • Receivables reached $182967.0 in Q4 2025 per INM's latest filing, down from $343469.0 in the prior quarter.
  • Across five years, Receivables topped out at $465104.0 in Q2 2025 and bottomed at $14842.0 in Q3 2021.
  • Average Receivables over 5 years is $161025.8, with a median of $81647.0 recorded in 2022.
  • Peak YoY movement for Receivables: skyrocketed 340.21% in 2023, then crashed 30.32% in 2025.
  • A 5-year view of Receivables shows it stood at $50304.0 in 2021, then skyrocketed by 62.31% to $81647.0 in 2022, then dropped by 18.21% to $66775.0 in 2023, then soared by 293.21% to $262569.0 in 2024, then crashed by 30.32% to $182967.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $182967.0 in Q4 2025, $343469.0 in Q3 2025, and $465104.0 in Q2 2025.